Diagnostics for All, Inc.
Global health initiatives are making great strides in the treatment of infectious and parasitic diseases. For example, roughly 3 million people in developing countries now receive anti-retroviral medications for HIV/AIDS and about 5.5 million people are being treated for TB. The drugs used to treat these diseases are highly potent and often harmful to patients when not closely monitored. The expanding ability to treat ever-larger populations with potent drugs intensifies the need to accurately and inexpensively diagnose and monitor large numbers of patients, often in resource poor settings where reliable electricity, clean water, and skilled medical professionals are not available.
DFA is a non-profit enterprise fusing biotechnology and microfluidics, dedicated to creating low-cost, easy-to-use, point-of-care diagnostics designed specifically for the 60% of the developing world that lives beyond the reach of urban hospitals and medical infrastructures. Our elegantly simple and inexpensive devices require minimal training to use, practically no sample preparation, and no electricity or additional equipment to process a sample. Results are displayed quickly in an easy-to-read format and all devices are compatible with telemedicine networks. Over the past several years, Professor George Whitesides and his team at Harvard University have pioneered the technology underlying our devices; and DFA holds an exclusive worldwide license for medical and other applications.